NDTV-Dettol Banega Swasth Swachh India NDTV-Dettol Banega Swasth Swachh India
  • Home/
  • News/
  • Centre May Purchase 300-400 Million Covishield Doses By July 2021: Serum Institute’s Adar Poonawalla

News

Centre May Purchase 300-400 Million Covishield Doses By July 2021: Serum Institute’s Adar Poonawalla

Serum Institute of India (SII) has partnered with global pharma giant AstraZeneca and Oxford University for the COVID-19 vaccine candidate ‘Covishield’

Centre May Purchase 300-400 Million Covishield Doses By July 2021: Serum Institute’s Adar Poonawalla
Highlights
  • On November 28, PM Modi visited the manufacturing facility of SII in Pune
  • For COVID vaccine distribution, SII’s priority is India and COVAX countries
  • SII has already produced 40-50 million doses of the vaccine: Mr Poonawalla

New Delhi: After Prime Minister Narendra Modi visited the company’s pandemic level facility in Pune, Serum Institute of India’s (SII), Chief Executive Officer (CEO) Adar Poonawalla on Saturday (November 28) said that indications suggest that the central government may purchase 300-400 million doses by July 2021. SII has partnered with global pharma giant AstraZeneca and Oxford University for the vaccine candidate ‘Covishield’. “As of now we don’t have anything in writing of how many doses the Government of India would purchase, but the indication is three to four hundred million doses by July 2021,” Mr Poonawalla said in a media interaction.

Also Read: Government Will Get COVID-19 Vaccine At Rs.250; 100 Million Doses By January, Serum Institute’s Adar Poonawalla On Oxford Vaccine

Mr Poonawalla also disclosed that the SII will apply for emergency authorisation of the COVID-19 vaccine in the next two weeks.

Talking about the progress of the vaccine, SII CEO said,

We are in the process of submitting the data of our vaccine to the Drug Control of India. After it is reviewed it will be the decision of the Health Ministry to roll out doses in the first and second quarters.

Responding to a question on the distribution of the vaccine, Mr Poonawalla stressed that the SII’s priority is India and other COVAX countries.

Vaccine will be distributed initially in India, and then we will look at the COVAX countries which are mainly in Africa. The UK and European markets are being taken care of by AstraZeneca and Oxford. Our priority is India and COVAX countries, he said.

Also Read: COVID-19: Entire Delhi Can Be Vaccinated In A Month, Says State Immunisation Officer

Talking about his interaction with Prime Minister, Mr Poonawala said he was amazed by his knowledge of vaccines.

Prime Minister Narendra Modi is extremely knowledgeable now on vaccines and vaccine production. We were amazed at what he already knew. There was very little to explain to him, except for going into detail on different variable vaccines and the challenges that they may face ahead, the CEO said.

Mr Poonawala further said the SII has already produced 40-50 million doses of the vaccine per month, and the pharma giant is planning to stretch it up to 100 million doses of the vaccine per month by February.

There was zero hospitalisation during the trial and 60 per cent reduction in sterilizing immunity, Mr Poonawalla disclosed about the Covishield vaccine in the virtual interaction.

Also Read: AstraZeneca CEO Expects To Run New Global Trial Of COVID-19 Vaccine

PM Modi visited the manufacturing facility of SII in Pune on Saturday (November 28), to personally review the vaccine development.

Had a good interaction with the team at Serum Institute of India. They shared details about their progress so far on how they plan to further ramp up vaccine manufacturing. Also took a look at their manufacturing facility, he wrote on Twitter.

In another tweet, the Prime Minister’s office said,

Prime Minister stressed that India considers vaccines as not only vital to good health but also as a global good, and it is India’s duty to assist other countries, including the nations in our neighbourhood, in the collective fight against the virus.

Also Read: AstraZeneca-Oxford COVID-19 Vaccine Faces Questions After Error: Report

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene

[corona_data_new]
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Highlights: Banega Swasth India Launches Season 10

Reckitt’s Commitment To A Better Future

India’s Unsung Heroes

Women’s Health

हिंदी में पढ़ें

This website follows the DNPA Code of Ethics

© Copyright NDTV Convergence Limited 2024. All rights reserved.